STUDIES ON NATURAL AND SYNTHETIC POLYMERS FOR CONTROLLED RELEASE MATRIX TABLET OF ACECLOFENAC

被引:0
作者
Joshi, Abhishek S. [1 ]
Joshi, Deepak A. [2 ]
Dhobale, Avinash, V [2 ]
Bundel, Sandhya S. [2 ]
Chakote, Vijay R. [2 ]
Dhembre, Gunesh N. [2 ]
机构
[1] IPCA Lab Ltd, Qual Assurance Dept, Silvasa, India
[2] SVP Coll Pharm B Pharm Hatta, Dept Pharmaceut, Hingoli 431705, Maharshtra, India
来源
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2018年 / 5卷 / 01期
关键词
Aceclofenac; guar gum; xanthan gum; CDDS and matrix tablets;
D O I
10.5281/zenodo.1149339
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The present study was aimed to design new oral controlled release matrix tablets of new NSAID Aceclofenac for once a day by using 10, 15, 20 and 25% of GG:HPMC and XG:HPMC mixture in the ratio 1:1 by wet granulation method. The prepared tablets subjected to in vitro drug release studies in pH 7.4 buffer solution. All the formulation meets the pre-compression and compression characteristics. All the tablets prepared with 10, 15, 20 and 25% of HPMC: XG mixture in the ratio 1:1 fails to meet the requirement of complete release of the drug in 24h. The tablet formulations containing 10% and 15% of GG: HPMC mixture fails to control release of drug upto 24h. The formulation AHG20 controlled release of drug upto 24h and released more than 97% of the drug in 24h. Hence considered as the best formulation. The optimized tablet batch formulations AHG20 showed no change in drug content or in vitro release pattern after storage at 40 degrees C / 75% RH for 30 days. The FTIR studies indicated absence of interaction between aceclofenac and tablet excipients used in the matrix tablets. It has been observed from the above study that excipients like HPMC, xanthan gum, guar gum and microcrystalline cellulose were ideal excipients and effective for formulating controlled release matrix tablets. As these excipients are easily available, inexpensive and compatible. Controlled release matrix tablets provide several advantages reduce dose related toxicity, reduce drug waste and improve patient compliance.
引用
收藏
页码:304 / 312
页数:9
相关论文
共 19 条
  • [1] Ansari M.T., 2017, INT J PHARM BIO SCI, V8, P21, DOI [10.22376/ijpbs.2017.8.4.p21-29, DOI 10.22376/IJPBS.2017.8.4.P21-29]
  • [2] Bhowmik D, 2012, PHARM INNOVATIONS, V1, P29
  • [3] Brahmankar DM., 2009, BIOPHARMACEUTICS PHA, P399
  • [4] Chein YW., 2002, NOVEL DRUG DELIVERY, V50, P139
  • [5] Chugh I, 2012, INT RES J PHARM, V3, P57
  • [6] Grass MG, 1990, MODERN PHARM, P635
  • [7] Gupta PK, 1992, TREATISE CONTROLLED, P255
  • [8] Jaimini M., 2012, J DRUG DELIV THER, V2, P142
  • [9] Kumar A., 2013, IJOPILS, V1, P1
  • [10] Kumar KS, 2012, J PHARM INNOV, V1, P48